VALENTIS - REBOUND MIT ANSAGE - 500 Beiträge pro Seite

[bioperformer]

@all

Da es bislang scheinbar keinen eigenen Thread zu VALENTIS gibt, will ich das mal ganz schnell ändern.

Im Zuge der derzeitigen Erholung bei den extrem verprügelten Biotechs steht meiner Meinung nach VLTS kurz vor einem deutlichen Kurssprung.

Dafür sprechen neben der deutlichen Unterbewertung im Bezug auf die derzeitige Marktkapitalisierung von nur rund 28 Mio. US$ vor allem der hohe Eigenkapitalbestand von gut 15,5 Mio US$, aber vor allem auch eine durchaus nicht uninteressante Pipeline.


http://www.valentis.com/products/pipeline.html



Auch ein Blick auf den mitgebrachten Chart dürfte den Wert nicht unsympatisch erscheinen lassen.






Nicht verschwiegen sollte allerdings auch werden, daß bei nur ca. 13 Mio. Shares eine gewisse Marktenge auftreten könnte. Dies kann sich positiv wie auch negativ auswirken, bei Orders in USA dürfte es da weniger Probleme mit der Verfügbarkeit geben.



Grüße, Bio

[quantensprung]

Hallo bioperformer

Schön das es jetzt einen Thread zu VALENTIS gibt.
Ich habe letzte Woche eine erste Position bei 2,13$ aufgebaut. Bei einen Schlußkurs über 2,5 werde ich aufstocken.
Ich rechne mit einem baldigen Ausbruch und Kursen um 4$.

Grüße
quantensprung

[bioperformer]

Hallo Quantensprung,

....wußte ich es doch, daß ich nicht ganz allein im weiten Anlegerland mit meiner Erstposition bei VALENTIS bin.

Ich stelle dir bei Gelegenheit mal ein paar ganz interessante Begebenheiten zum Thema Insiderkäufe und Ähnlichem rein.


Gruß,Bio

[bioperformer]

@all

2,45 US$ ist derzeit das Maß der Dinge - zumindest aus charttechnischer Sicht. Wird diese Marke genommen, ist der nächste Widerstand erst in der Gegend um 4,70 US$ erkennbar.

Bei diesem relativ engen Wert wäre ich dann nicht mehr gerne short...

[bioperformer]

@all


SHORTRATE STAND 15.12.04

Dec. 15, 2004 376,584 178,593 2.11
Nov. 15, 2004 468,889 145,868 3.21
Oct. 15, 2004 776,142 784,154 1.00
Sep. 15, 2004 685,497 175,030 3.92
Aug. 13, 2004 761,462 154,746 4.92

[quantensprung]

Ich glaube wir müssen nicht mehr lange auf den Ausbruch warten. Aktuell 2.45

Gruß

[bioperformer]

hallo Quantensprung,

allmählich fängt man an sich mit VLTS zu beschäftigen.
Beim Blick auf den real vorhandenen "Wertbestand" werden sich manche verdutzt die Augen gerieben haben.
VALENTIS hat bei einer Marktkapitalisierung von ca. 29 Mio. US$ immerhin gut die Hälfte - 15,5 Mio.- an eigenen Mitteln aufzuweisen.

Allein schon deshalb sehe ich nur wenig Rückschlagpotenzial beim Kurs, nebenbei gesagt wirst du derzeit nicht viele Bios mit diesem Kurs/Vermögenswerte-Verhältnis finden.

Fortschritt im Bereich der Forschung ist da noch nicht mal inclusive.


Gruß, Bio

[Kenny4Cash]

Ich bin auch grad auf den Wert gestoßen und wollt mal fragen ob einer weiß, wann die trial für Deltavasc begonnen hat bzw mit der Veröffentlichung zu rechnen ist.

@bioperformer
Wie man an deinem Depot sieht,spielst du entweder gerne Pocker oder scheinst dir ja mit dem baldigen Ausbruch ziehmlich sicher zu sein. Meinst du die bricht noch in diesem Jahr aus?

Kenny4Cash

[bioperformer]

@all

bin gerade auf einen nicht mehr besonders aktuellen, weil schon aus Mitte 2004 resultierenden Researchreport gestoßen. Stelle den mal nachfolgend rein, verweise aber ausdrücklich darauf, mich selbst bislang noch nicht allen Seiten gewidmet zu haben.

http://www.cohenresearch.com/reports/vlts_07-14-04.pdf


Sieht so aus als wären da doch einige wissenswerte Dinge darin enthalten. Viel Spaß beim Stöbern.


@Kenny4Cash


Pokern ist machmal ganz okay, nicht aber grundsätzlich!

Zum Thema Ausbruch bin ich mir ziemlich sicher. Wenn nicht heute, dann halt in "Bälde". Habe mich real relativ dicke mit VLTS eingedeckt


Gruß Bio

[Kenny4Cash]

hab dann mal das selbige getan und mir zu 2,43 einen Haufen ins Depot gelegt

[quantensprung]

EMA 50 verläuft bei 2,48 sollten wir diese Linie durchbrechen kann es sehr schnell nach oben gehen.
Ich habe eine Stoppbuy Order bei 2,50.

Bio, danke für den Researchreport.

Grüße
quantensprung

[derschweizer]

@biopeformer

Ich hätte da eine Frage bezüglich des Kursrutsches im Oktober. Gab es da irgendwelche Bad News, oder eine Kapitalerhöhung?
Was war der genaue Grund?
Ich konnte nichts finden, oder war Blind
Ansonsten gefällt mir Valentis ausgesprochen gut.

Präsentation Dez.2004

http://www.valentis.com/content/valentis_corp_presentation.p…

grüße derschweizer

[quantensprung]

@ derschweizer



Last Update: 1:14 PM ET Sept. 29, 2004 (CBS.MW) -- Shares of Valentis Inc plummeted Wednesday after the company said a trial of the use of Deltavasc, its lead product, missed its primary endpoint of relieving muscle pain in people with heart disease against a control group.



The company`s stock dropped $3.79, or 57.4 percent, to $2.81 in afternoon action. Earlier in the session, it scraped a 52-week low of $1.90. Volume of 5.4 million was more than 32 times the issue`s daily average of 168,200.

The phase II trial included peripheral arterial disease patients suffering from intermittent claudication, or muscle pain, when they exercise. Its primary endpoint was the improvement of exercise tolerance after a 90-day period versus a control group.

Valentis (VLTS: news, chart, profile), which is based in Burlingame, Calif., said there was a "statistically significant increase" in exercise tolerance in both the group treated with Deltavasc, which is the Del-1 gene and the company`s proprietary PINC polymer delivery system, and the group that received just the PINC polymer.

In fact, the group receiving just the PINC polymer saw an increase in exercise tolerance from baseline of 34 percent, while the Deltavasc group saw an increase from baseline of 32 percent.

"While we were surprised with the lack of difference in the two treatment groups in this trial, we believe there is sufficient evidence from our Phase II trial to warrant a pivotal trial of PINC polymer in peripheral arterial disease," said Benjamin McGraw, the company`s chairman, in a press release.

He continued: "If (the) PINC polymer demonstrates similar efficacy and safety in subsequent clinical trials, we intend to bring to market a product that is safer with more convenient dosing and potentially better efficacy than currently available products for peripheral arterial disease."

The company also said it plans to conduct a trial of Deltavasc for a non-cardiovascular indication.

[Kenny4Cash]

... und ich glaube auch heute ist der Tag schon über 100k stk (gestern warns grad mal 200k)und 2,49 $

[bioperformer]

@derschweizer

..das dürfte der Auslöser für den Absturz gewesen sein:


Valentis Reports Results in Phase II Clinical Trial of Deltavasc(TM) in Peripheral Arterial Disease
Study Misses Primary Endpoint but Finds Statistically Significant Improvement

in Exercise Tolerance and Ankle Brachial Index in Patients Treated With
PINC(TM) Polymer

Conference Call to be Held at 1:00pm ET, September 29, 2004

BURLINGAME, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Valentis, Inc. (Nasdaq: VLTS) announced today that its Deltavasc(TM) product did not meet its primary endpoint in a Phase II clinical trial in patients with the intermittent claudication form of peripheral arterial disease. The primary efficacy endpoint in the study was improvement in exercise tolerance after 90 days with the Deltavasc(TM) product versus control. Patients in the Phase II clinical trial were randomized equally to receive either Deltavasc(TM) (Del-1 gene plus PINC(TM) polymer) or PINC(TM) polymer alone, which acted as the control agent in the clinical study.

Data from the trial indicate that both treatment arms were, in fact, active. There was a statistically significant increase in exercise tolerance from baseline in both the Deltavasc(TM) (Del-1 gene plus PINC(TM) polymer) and PINC(TM) polymer treatment groups. Importantly, there was also a statistically significant improvement in ankle brachial index (ABI), a clinical indicator of blood flow, in both the Deltavasc(TM) and PINC(TM) polymer treatment groups. The improvement in exercise tolerance in both groups was virtually identical and well above the 14% or less placebo effect observed in previous trials of similar design. The finding of statistically significant improvement in ABI concomitant with improvements in exercise tolerance is supportive of the exercise results and it points to a hemodynamic mechanism for the therapeutic effect of the PINC(TM) polymer. Importantly, there was also a statistically significant correlation between improvement in peak walking time and improvement in ankle brachial index.

At the 90-day assessment, the PINC(TM) polymer group of 51 patients had a significant increase in exercise tolerance from baseline of 34% (p<0.00001) and the Deltavasc(TM) group of 49 patients had a significant increase in exercise tolerance from baseline of 32% (p=0.0001). Importantly, the change in ankle brachial index was also statistically significant in both groups. In the group receiving PINC(TM) polymer, there was an increase in ankle brachial index of 0.059 (p=0.00072). For the group receiving PINC(TM) polymer plus Del-1, there was an increase in ankle brachial index of 0.048 (p=0.00665). The correlation between improvement in peak walking time and the improvement in ankle brachial index was statistically significant (p=0.039). Both Deltavasc(TM) and the PINC(TM) polymer were well tolerated. Patient demographics and results of secondary endpoints were virtually identical.

Benjamin F. McGraw, III, Pharm.D. Chairman, President and CEO stated, "While we were surprised with the lack of difference in the two treatment groups in this trial, we believe there is sufficient evidence from our Phase II trial to warrant a pivotal trial of PINC(TM) polymer in peripheral arterial disease. If PINC(TM) polymer demonstrates similar efficacy and safety in subsequent clinical trials, we intend to bring to market a product that is safer with more convenient dosing and potentially better efficacy than currently available products for peripheral arterial disease. We also plan to initiate a trial of Deltavasc(TM) in a non-cardiovascular indication. Based on the preclinical studies completed to date, Del-1 is clearly an angiogenic agent. We will continue to evaluate opportunities for this product in cardiovascular indications."

Phase II Trial Design

This was a randomized, double-blind, placebo-controlled trial of 100 patients at 17 centers in the US. The primary endpoint was change in exercise tolerance at 90 days in patients receiving Deltavasc(TM) versus those receiving PINC(TM) polymer. Patients were randomized equally to receive either 84 mg of Deltavasc(TM), which is a formulation of a 5% solution of PINC(TM) polymer mixed with the Del-1 gene, or a 5% solution of the PINC(TM) polymer alone. The PINC(TM) polymer was mixed with the Del-1 gene because PINC(TM) polymer is believed to be active on cell membranes, which increases the uptake of the gene. This PINC(TM) polymer is a non-ionic polyoxyethylene-polyoxypropylene block copolymer, which has the chemical characteristics of components of cell membranes. Patients eligible for entry into the trial had evidence of active intermittent claudication at baseline.

Valentis Conference Call

Valentis will be hosting a conference call and webcast today at 1:00 p.m. EDT to discuss the results of the Phase II Deltavasc(TM) clinical trial. To participate in the audio portion of the call, dial 800-322-0079 for domestic callers, and 973-409-9258 for international callers. A link to the webcast of the audio portion of the call will be available on the Investor Relations section of the Company`s website, under the "Investor Relations" tab at www.valentis.com

A replay will be available at http://www.valentis.com starting approximately one hour after completion of the webcast.

About Valentis

Valentis is creating innovative cardiovascular therapeutics. The company begins its product development at the stage of a validated target and applies its expertise in formulation, manufacturing, clinical development and regulatory affairs to create products that fill unmet medical needs. Valentis has a series of technologies that allow the company to generate novel therapeutics to treat a wide range of diseases. While Valentis is focusing its efforts on the development of novel cardiovascular therapeutics, its technologies are being applied by its collaborators for the development of therapeutics to treat a variety of indications including infectious diseases and cancer.

Additional information about Valentis can be found at www.valentis.com.

This press release contains forward-looking statements regarding potential products based on PINC(TM) polymer for treatment of peripheral arterial disease, statements regarding the potential efficacy, safety and convenient dosing of PINC(TM) polymer, plans to initiate a trial of Deltavasc in a non-cardiovascular indication and Valentis ability to develop PINC(TM) polymer for treatment of peripheral arterial disease. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict. In particular, results obtained regarding PINC(TM) polymer as a result of the Phase II clinical trial of Valentis` Deltavasc(TM) product may not be predictive of results to be obtained in a pivotal trial of PINC(TM) polymer in peripheral arterial disease. Additional factors that could cause actual results to differ include risks related the initiation and conduct of a new clinical trial of PINC(TM) polymer, potential changes in study protocols, ability to enroll additional patients, ability to protect the intellectual property related to development of PINC(TM) polymer, the need for additional capital, uncertainties related to the timing of completing clinical trials, uncertainties related to the costs of completing clinical trials and whether clinical trial results will validate and support the safety and efficacy of a PINC(TM) polymer-based product. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Valentis will be able to commercially develop such product. Actual results may also differ from those projected in forward-looking statements due to risks and uncertainties that exist in the Company`s operations and business environments. These risks and uncertainties are described more fully in the Valentis Annual Report on Form 10-K for the period ended June 30, 2004, as filed with the Securities and Exchange Commission on September 15, 2004. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SOURCE Valentis, Inc.



Gruß, Bio

[derschweizer]

@all

Danke,
alles klar, habe mich im Monat verhauen(Sept.nicht Okt.).
Seht ihr Valentis fundamental als kurz, mittel oder langfristiges Investment, oder eher momentan aus charttechnischer Sicht?

derschweizer

[therman]

Hi,

ich sehe VLTS vorerst aus charttechnischer Sicht als sehr
interessant an. Bullishe Divergenzen.
Vielen Dank an bioperformer, durch ihn bin ich auf VLTS
erst aufmerksam geworden.

Bin heute zu 2,35 eingestiegen.

Könnte aber auch mittel und langfristig interessant sein.
Bleibt auf jeden Fall auf meiner Watchlist.

therman

[bioperformer]

@derschweizer

weil ich dir sonst nichts zu Weihnachten geschenkt habe, anbei meine Spekulation bei VLTS

Ich gehe aus mehreren Gründen von einem schnellen Double aus. 50/50 Split, verbleibender Rest mit Laufzeit ultimo und Kursziel "extrafett".

So, oder so ähnlich stelle ich mir das mal vor. Ein Blick auf den Langfristchart bestätigt zumindest daß dieses Szenario nicht unmöglich ist.

Noch so ganz am Rande vermute ich ähnliches Gedankengut auch als einen der Hauptgründe für das Festhalten an einer doch ganz beachtlichen Menge Shares die sich im Besitz des SOROS-FUNDS befinden. Auch dort hat man offensichtlich nicht ausverkauft.


Gruß, Bio

[sir_bob]

so ... dann kanns ja los gehen !

hier noch einige Infos :

Valentis, Inc. creates cardiovascular therapeutics. The Company begins the product development at the stage of a gene or protein with known activity and applies the expertise in formulation, manufacturing, clinical development and regulatory affairs to create products that fill unmet medical needs. Valentis has a series of technologies ranging from gene delivery and expression technologies to formulation and manufacturing technologies that allow the Company to generate novel therapeutics to treat a wide range of diseases. While Valentis is focusing its efforts on the development of cardiovascular therapeutics, its technologies are being applied by its collaborators for the development of therapeutics to treat a variety of indications, including infectious diseases and cancer. The merger of Megabios Corp. and GeneMedicine, Inc. in March 1999, formed Valentis Inc. In August 1999, Valentis acquired United Kingdom-based PolyMASC Pharmaceuticals plc.

Deltavasc, the Company`s product, is based on the developmentally regulated Endothelial cell Locus-1 (Del-1) angiogenesis gene formulated with a Valentis polymeric non-condensing (PINC) polymer delivery system. Deltavasc is in Phase II clinical trials in patients with the intermittent claudication (IC) form of peripheral arterial disease (PAD). The primary endpoint in this trial is improvement in exercise tolerance 90 days after dosing of the product. The Company`s products contain genes formulated with synthetic delivery systems that are administered to specific tissues where they enter targeted cells. These cells then produce the therapeutic protein or vaccine antigen.

Gene delivery

Valentis has developed chemical-based technologies for the delivery of genes. Valentis has developed synthetic gene delivery systems based on several classes of polymers. The PINC polymers are designed to provide efficient delivery to a variety of tissues, including muscle and solid tumors. The ability of Valentis` polymer delivery systems to enhance cellular distribution and uptake of genes in vivo has resulted in the production of therapeutic levels of proteins. Valentis` cationic lipid delivery systems provide delivery after intravenous, aerosol or intra-tumoral administration. These delivery systems have been used in clinical trials for each of these applications. Valentis has developed synthetic vaccine delivery systems based on several classes of polymers. The deoxyribonucleic acid (DNA) Vax polymer-based delivery systems for intramuscular administration of vaccines provide for higher and more consistent levels of antigen production.

Hermes gene expression systems

Valentis` Hermes expression systems are plasmids developed by the Company. A plasmid is a circle of DNA that includes the gene for a therapeutic protein. Also included in plasmids are elements that control the production of the message from that gene. This message serves as the code or blueprint for the production of the therapeutic protein by cells. Once plasmids are delivered into cells, they operate episomally, which means they are not incorporated in the DNA of the cell.

Valentis` plasmids have been engineered to provide increased gene expression (production of the message for protein production). In the plasmids, the Company incorporates high-expression promoters into expression cassettes. These cassettes contain novel untranslated regions with synthetically designed introns. Included in the library of plasmids are those with tissue specific promoters.

GeneSwitch gene regulation

Valentis` GeneSwitch permits therapeutic protein production that is controlled via an orally administered drug. Products incorporating the GeneSwitch technology are delivered with a polymer delivery system along with electroporation. This results in controlled production of therapeutic proteins from muscle tissue for prolonged periods.

The competitors of the Company include AnGes MG, Aventis Pharma SA, Avigen, Inc., Cell Genesys, Inc., Corautus Genetics, Daiichi Pharmaceutical Corporation, Gencell SAS, GenVec, Inc., Introgen Therapeutics, Inc., Schering AG, Targeted Genetics Corp. and Vical Inc.

[quantensprung]

Nachdem gestern die EMA50 nachhaltig durchbrochen wurde, sollte es jetzt schnell Richtung 4USD gehen.Kann durchaus sein, dass wir 20-30% Plus an einem der nächsten Tage sehen.

Einen guten Rutsch und viel Gewinn 2005 euch allen!
quantensprung

[bioperformer]

@all


...in diesem Sinne allen VLTS-Mitinvestoren einen guten Jahresausklang, einen besseren Jahresanfang, Gesundheit und erfolgreiche Trades in 2005.

Zur Unterstützung beim Durchbruch habe ich noch mitgebracht...


Grüße, Bio

[bioperformer]

da scheint es aber jemand mächtig eilig zu haben ...

schon 2k fur 2,74 über den Tresen...

[quantensprung]

Insgesamt 11k bei 2,74-2,75USD

[sir_bob]

mal sehen .. ich hab auch nochmal ein paar eingesammelt

[Nekrophillus]

wartet ich glaub die gibs heute noch billiger!Bullenfalle?

[Kenny4Cash]

Sind das heut nur Gewinnmitnahmen oder wieso fällt der Kurs?

[therman]

Hi,

heute deutlicher Kursrückgang, der von der 20-Tagelinie
aufgefangen wird, die bei 2,31 verläuft.

Sollte die 20-Tagelinie durchbrochen werden, ist ein Pullback bis 2$ wahrscheinlich.
Die sollten dann allerdings halten.

therman

[bioperformer]

..mal von heute und gestern abgesehen konnte man - sofern man sich mal die Schlußviertelstunde im US-Handel zu Gemüte geführt hat - doch jeweils das gleiche Spielchen beobachten.
Mit nur wenigen Stücken wurde da der Kurs teilweise in den letzten zwei Minuten doch teilweise deftig gedrückt. Da dies an mehreren Tagen in Folge passierte, sonst aber das Kursniveau des Vortages nicht massiv zu unterbieten versucht wurde läßt mich vermuten, daß da noch jemand mit größeren Stückzahlen rein wollte ohne den Kurs massiv nach oben zu pushen. Die in diesen Tagen gehandelten Stückzahlen dürften diese Theorie unterstützen.

Der heutige Abschlag dürfte wohl eher dem Marktumfeld der Bios im Allgemeinen, sowie der ungünstigen charttechnischen Situation Rechnung tragen. Zumindest ist mir nichts negatives bezüglich VLTS bekannt geworden.

Wie auch immer, therman hat aus charttechnischer Sicht heraus bereits berichtet was evtl. zu erwarten ist. Ich schließe mich dem an, werde aber trotzdem kein Stück abgeben und wünsche noch was...


Grüße, Bio

[Kenny4Cash]

Hmm befinden wir uns derzeit in ner Seitwertsbewegung? In den letzen Tagen waren ja in dem Kurs starke Schwankungen zu sehen, durch lausige 100 Stückpackete wird der Kurs ständig gedrückt, das hat Taktik. Außerdem hat sich der Umsatz in den letzten Tagen fast halbiert.

Hat jemand ne Idee in welche Richtung es weiter geht?

Kenny4Cash

[bioperformer]

hallo kenny,


....habe mal die alte Hexe in meinem Keller befragt, sie meint daß im Lauf dieser Woche nicht mehr viel passiert...


Aber jetzt mal ganz trocken betrachtet:

Habe den Eindruck, daß - wie auch schon in meinem letzten Posting berichtet - da jemand versucht größere Stückzahlen ohne Kursexplosion einzusammeln. Das ist, wie wir wissen hier wegen einer doch gewissen Marktenge nicht ganz so problemlos möglich. Deshalb funktioniert das mit dem Einsammeln hier nur über den Faktor Zeit.

Die starken Kursschwankungen dürften ebenfalls gewollt sein, haben halt den Zweck möglichst viele Stops auszulösen.


Gruß, Bio

[therman]

Hi,

bei VLTS bietet sich zur Zeit eine gute Gelegenheit zum Einsteigen, denke ich.

therman

[Kenny4Cash]

So lange da noch einige versuchen um die 2.20 rein zu kommen, es in 5 Tagen nicht geschafft haben den Kurs nachhaltig unter 2.20 zu drücken, hält er sich sehr stabil und wird langsam steigen. Zum anderen scheinen die Transaktionen beendet, haben bis jetzt grade mal 50k Stück, was dafür spricht das nun der Markt wieder den Kurs bestimmen kann und aktuell 2.30$ ... gut so.

Kenny4Cash

[Kenny4Cash]

Hui heute steiler Anstieg trotz geringen Volumens, aktuell 2,42 $ heißt das, dass um 2,2x alles aufgekauft wurde? Zumindest laut Orderbuch steht nichts unter 2,43 $ mehr drin und bis 2,45 $ ist es ein lockerer Durchlauf.

Gibts ne Einschätzung?

Kenny4Cash

[quantensprung]

Chart sieht super aus. Stochastik gab Kaufsignal.MACD steigt wieder. EMA20 wurde durchbrochen. Aktuell bei 2.44 hier verläuft EMA50.

[quantensprung]

EMA50 wurde durchbrochen. Kurs 2,51USD
2,75USD letzter Widerstand.

Gruß

[bioperformer]

..was ist das denn?


VK in Frankfurt___ 6____ Stck. zu 1,85

Nachdem es sich hierbei wohl nicht um einen SL handelt, muß das wohl unter der Rubrik Gewinnmitnahmen eingeordnet werden....

[Kenny4Cash]

@bioperformer

Was sagt deine Kugel für diese Woche, Handel ist ja ziehmlich stark abgeflacht und schon mit geringen Summen läßt sich der Kurs auf 2,2x drücken obwohl es zum Ende letzter Woche eigentlich mit zeitweise über 2,50 ganz nett aussah.
Heute bis jetzt 0 Stk. Umsatz und nem Ask was zwischen 2,3 und 2,4 schwankt und trotzdem 0 Stk.
Will den keine mehr Valentis kaufen?

MfG

Kenny4Cash

[Kenny4Cash]

Ach wegen dem 0 Stk. Umsatz, sorry ich merk grad das man Scotti mal wieder vergessen kann.

Kenny$Cash

[bioperformer]

Hallo Kenny,

...Rest der Woche grün

Bios ( meine zumindest) sind die letzten Tage alle nicht besonders doll gelaufen, VLTS hat da im Vergleich noch wenig im Kurs nachgegeben.

Ich denke, das wird schnell wieder aufgeholt sein...

Gruß, Bio

[Kenny4Cash]

@bioperformer
Ich glaub so Kugel brauch ich auch
Mit nem Schlusskurs von 2,50 hätt ich heut am wenigsten gerechnet, Volumen 136k sind 50k mehr als gestern und die schöne weise Kerze läßt auf nen guten Start morgen hoffen, besonders wenn man den aktuellen Bid/Ask mit 2,40/ 2,74 glauben schenken kann.
Aber nichts überstürtzen und sehn was der morgige Tag bringt.

MfG

Kenny4Cash

[bioperformer]

@kenny4cash

extra für dich....


grüüüüüüühhhhhhhn

[bioperformer]

@all

SHORT INTEREST STAND 14.01.2005


Jan. 14, 2005 385,407 180,207 2.14
Dec. 15, 2004 376,584 178,593 2.11
Nov. 15, 2004 468,889 145,868 3.21
Oct. 15, 2004 776,142 784,154 1.00
Sep. 15, 2004 685,497 175,030 3.92
Aug. 13, 2004 761,462 154,746 4.92
Jul. 15, 2004 665,540 163,589 4.07

[quantensprung]

Ich habe gestern bei 2,6 USD verkauft. Stochastik gab Verkaufssignal und MACD fällt auch wieder. Sieht so aus als ob jemand den Kurs unter 2,7 USD halten wollte.

Grüße

[yoppu]

abwarten, waren ja gestern keine Umsätze da!

[Kenny4Cash]

Mal ne andere Frage, wieviele Aktien von denen werden überhaupt durch Anleger gehalten, mir kommt es bei dem Spread von immer so mind. 10 cent Differenz zwischen Bid und Ask vor als würde keiner verkaufen aber auch keiner kaufen wollen und dem Orderbuch zufolge würden geringe Mengen reichen um sie entweder zu puschen oder zu drücken.
Jemand ne Idee?

Kenny4Cash

[bioperformer]

hallo Kenny,

in puncto Anteilsverhältnisse der Institutionellen zu Privatanlegern kann ich dir mit ein paar Zahlen aushelfen.

Meiner Info nach sind da ca. 25 Institutionelle Investoren beteiligt. Zusammen halten diese 41,06% oder auch 5.378.351 Shares.
Der verbleibende Rest von 7.720.411 Shares dürfte sich somit in Händen von Privatanlegern befinden, wobei sich meines Erachtens nach durchaus eine jeweils nicht zu knappe Portion auch im Besitz von Einzelnen befinden könnte.

Richtigerweise hast du bemerkt, daß wegen der schon bereits angesprochenen Marktenge noch eine Art "Verstärker" mit von der Partie ist. Der kann allerdings auch schnell mal die Reise in den Süden anleiern...


Gruß, Bio

[bioperformer]

...da kommt was..

[bioperformer]

@all

Im Hinblick auf die derzeit grassierende Seuche bei den meisten Bio´s hat sich VLTS diese Woche nicht nur bestens gehalten, sondern auch noch auf Wochenhoch geschlossen.

Komliment an den "Einsammler" in USA, hat er es doch geschafft ohne signifikante Veränderung des Kursniveaus ordentlich und fast unbemerkt einzusacken.

Wie geht es aber jetzt weiter?

Darauf bieten sich zwei Theorien an:

1.) In Bälde (genaues Datum habe ich noch nicht) müssten die neuen Q-Zahlen bekanntgegeben werden. Entweder sind diese so schlecht - was ich allerdings nicht glaube - und bereits im Vorfeld haben die "Großen" bereits mal dezent und möglichst kursschonend abgegeben.


2.) Insider wissen daß positive News anstehen und haben sich mit ihren Käufen wegen einer doch gewissen Marktenge frühzeitig positioniert um noch auf diesem Kurslevel Stücke einzusammeln.


Wie auch immer, beides ist möglich. Für überwiegend wahrscheinlich halte ich jedoch die zweite Version.
Auch aus charttechnischer Sicht dürfte da wohl eher der Ausbruch favorisiert werden. Kursziele jenseits der 5 US$-Marke, die bereits herumgeistern setze ich mir nicht für die nächste Woche, jedoch sehe ich die Zwei vor dem Komma als fast gegessen an.


Grüße, Bio

[bioperformer]

Form 10-Q for VALENTIS INC


--------------------------------------------------------------------------------

14-Feb-2005

Quarterly Report



ITEM 2: MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The discussion in "Management`s Discussion and Analysis of Financial Condition and Results of Operations" contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "projects," and other words of similar import or the negative of those terms or expressions. Forward-looking statements in this section include, but are not limited to, expectations of future levels of research and development spending, general and administrative spending, levels of capital expenditures and operating results, results of preclinical studies, plans for and the timing of additional clinical trials, sufficiency of our capital resources and our intention to seek revenue from the licensing of our proprietary manufacturing technologies. Forward-looking statements subject to certain known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could affect our actual results include the early stage of development of our products, uncertainties related to the timing of completing clinical trials, the need for additional capital and whether clinical trial results will validate and support the safety and efficacy of our products. Further, there can be no assurance that the necessary regulatory approvals will be obtained, that we will be able to develop commercially viable gene-based products or that any of our programs will be partnered with pharmaceutical partners. Actual results may differ materially from those projected in such forward-looking statements as a result of the "Additional Factors That May Affect Future Results" described below and other risks detailed in our reports filed with the Securities and Exchange Commission. We undertake no obligation to revise or update any such forward-looking statements.


OVERVIEW



VLTS 934 PRODUCT FOR THE In September 2004, we reported the results of our
TREATMENT OF PERIPHERAL Deltavasc™ Phase IIa clinical trial in peripheral
ARTERIAL DISEASE arterial disease. Briefly, both the Deltavasc™ and
the VLTS 934 groups demonstrated statistically
significant improvements in exercise tolerance (Peak
Walk Time, PWT) and ankle brachial index (ABI)
compared to baseline with no significant differences
between treatment groups. The unforeseen results
observed in both groups led to additional
intellectual property filings in anticipation of our
next phase of product development. We anticipate that
we will begin a follow-on Phase IIb clinical trial
using our VLTS 934 product compared to a saline
placebo in the quarter ending June 30, 2005.

VLTS 934 is an investigational product that is a
non-ionic polyoxyethylene-polyoxypropylene block
copolymer, which has the chemical characteristics of
components of cell membranes. We are currently
investigating the poloxamer`s possible mechanism of
action. The poloxamer may improve microvascular blood
flow by increasing local adenosine (a nucleoside that
is present in all living cells) levels. We are
conducting further preclinical studies to better
understand possible effects the poloxamer may have on
vasodilation, particularly in light of possible
sustained effects resulting from intramuscular
administration. These studies may help us better
understand potential effects at the arteriolar and
capillary level and how the poloxamer may exert a
pharmacologic effect over a prolonged period. These
hypotheses would be consistent with the concomitant
improvement in ankle brachial index observed in our
Phase IIa trial.

TECHNOLOGIES Valentis` synthetic gene delivery systems provide
efficient delivery after intramuscular, intravenous
or intratumoral administration. These delivery
systems are designed to enhance cellular distribution
and uptake of genes in vivo and to permit the
achievement of therapeutic levels of proteins.

Valentis` PINC™ polymers are designed to provide
efficient delivery to a variety of tissues, including
muscle and solid tumors.

Valentis` GeneSwitch® gene regulation technology
permits therapeutic protein production that is
controlled via an orally administered drug. Products
incorporating our GeneSwitch® gene regulation
technology are delivered with a polymer delivery
system and electroporation. This results in
controlled production of therapeutic proteins from
muscle tissue for prolonged periods. In research
applications, and particularly with transgenics, the
GeneSwitch® system is widely appreciated for its
ability to permit the study of otherwise lethal
mutations.

Valentis` expertise can assist in the selection of
appropriate PINC™ polymers or other synthetic
delivery technologies depending on the indication.
Licensing of these technologies is available.

GMP MANUFACTURING We have devoted substantial resources for the
development of scaleable, proprietary GMP
manufacturing for plasmid DNA-based therapeutics. We
have demonstrated that we can successfully
manufacture plasmid DNA containing therapeutic genes
from lab scale to commercial scale. Our methods are
distinctive because they are scaleable such that we
believe the same process can be used at all scales.
In addition to being of direct benefit to us in our
development of products, we intend to seek revenue
from the licensing of our proprietary manufacturing
technologies.






--------------------------------------------------------------------------------

RESULTS OF OPERATIONS

Overview

For the quarter ended December 31, 2004, we incurred significant losses primarily due to the advancement of our research and development programs and because we generated limited revenue. This is generally consistent with our performance since inception. We expect that operating results will fluctuate from quarter to quarter and that such fluctuations may be substantial. At December 31, 2004, our accumulated deficit was approximately $219.1 million. We expect to incur substantial losses for the foreseeable future and do not expect to generate revenue from the sale of products in the foreseeable future, if at all.

There have been no significant changes in our critical accounting policies during the six months ended December 31, 2004 as compared to what was previously disclosed in our Annual Report on Form 10-K for the year ended June 30, 2004 filed with the SEC on September 15, 2004.


Revenue

Revenue recognized in the three and six months ended December 31, 2004 and 2003
is as follows (in thousands):



Three Months Ended Six Months Ended
December 31, December 31,
2004 2003 2004 2003
License and other revenue
PEGylation $ - $ - $ - $ 6,500
GeneSwitch® gene regulation 110 1 687 210
PINCTM gene delivery - 250 550 250
Manufacturing technology 14 144 59 144
Total revenue $ 124 $ 395 $ 1,296 $ 7,104




Changes in revenue for the three and six months ended December 31, 2004 and 2003 are explained below:

• In July 2003, PolyMASC Pharmaceuticals, our wholly owed subsidiary, entered into a license and settlement agreement with ALZA Corporation, a unit of Johnson & Johnson. Under the agreement, PolyMASC settled its patent infringement litigation against ALZA and granted a worldwide, irrevocable and non-exclusive license to ALZA under its PEG-liposome patents. Non-recurring license revenue of $6.5 million was recognized from this agreement in the quarter ended September 30, 2003. No additional revenue is expected to be recognized under this agreement.

• The GeneSwitch® gene regulation revenue recognized in the three and six months ended December 31, 2004 and 2003 resulted primarly from license and annual license maintenance fees received under several agreements for ourGeneSwitch® gene regulation technology. GeneSwitch® revenue recognized in the six months ended December 31, 2004 included approximately $550,000 of license fee, received under an agreement with Schering AG in August 2004.

• The PINCTM gene delivery revenue recognized in the six months ended December 31, 2004 primarly reflects license fees received under an agreement with Schering AG. The PINCTMgene delivery revenue recognized in the three and six months ended December 31, 2003 resulted from the licensing of our PINCTM polymer based gene delivery system to Genencor International Inc. for the development of DNA vaccines against the hepatitis B virus (HBV) and the human papilloma virus (HPV).

• Manufacturing technology revenue consists of profit sharing and royalty revenue recognized under an agreement related to Valentis` plasmid DNA manufacturing technology.

Revenue derived from corporate collaborations and licenses helps us fund our operations and may increase in the future if we are successful in establishing new collaborations and additional licensing of our technology. We expect revenues for fiscal year 2005 to be less than revenues for fiscal year 2004 due to the recognition of the non-recourring license revenue from ALZA in fiscal 2004. If we are unsuccessful in establishing new collaborations or additional licensing of our technology, our revenues will decline and we may be required to limit our research and development, clinical trial, manufacturing and marketing efforts.

Research and Development Expenses

Research and development expenses dereased approximately $600,000 to approximately $1.8 million for the three months ended December 31, 2004, compared to approximately $2.4 million for the corresponding period in 2003. For the six months ended December 31, 2004, research and development expenses decreased approximately $100,000 to approximately $4.6 million, compared to approximately $4.7 million for the corresponding period in 2003. The decreases were primarily attributable to decreased expenses for the Deltavasc™ PAD Phase II clinical trial , which completed the dosing of patients in June 2004 and resulted in a fall off in clinical trial expesnes. We expect research and development spending in the future to increase from the current levels reflecting higher expenses associated with the commencement of the VLTS 934 Phase IIb clinical trial currently planned to begin in the quarter ending June 30, 2005.

Our research and development expenses currently include costs for scientific personnel, animal studies, supplies, equipment, consultants, patent filings, overhead allocation, human trials and sponsored research at academic and research institutions. In general, biopharmaceutical development involves a series of steps-beginning with identification of a potential target and including, among others, proof of concept in animal studies and Phase I, II, and III clinical studies in humans-each of which is typically more expensive than the previous step.

General and Administrative Expenses

General and administrative expenses remained at the same level of approximately $900,000 for the three months ended December 31, 2004 as compared to the corresponding period in 2003. For the six months ended December 31, 2004, general and administrative expenses increased approximately $400,000 to approximately $2.3 million, compared to approximately $1.9 million for the corresponding period in 2003. The increase was attributable primarily to expenses recorded in the quarter ended September 30, 2004 for the issuance of warrants to four individuals who are non-employees of the Company. We expect general and administrative spending in the future to decrease from the current level because warrant expenses recorded in the quarter ended September 30, 2004 were non-recurring.



--------------------------------------------------------------------------------

Interest Income and Other Expenses, net

Interest income and other expenses, net, increased by approximately $64,000 to approximately $75,000 for the three months ended December 31, 2004, compared to approximately $11,000 in the corresponding period of 2003. For the six months ended December 31, 2004, interest income and other expenses, net, increased by approximately $123,000 to a net interest income of approximately $105,000, compared to a net other expenses of approximately $18,000 in the corresponding period of 2003.The increases in interest income and other expenses, net, for the three and six month periods ended December 31, 2004 primarily reflected the increased interest income earned due to higher investment balances in the three and six months ended December 31, 2004 following the completion of the June 2004 private placement of our common stock and warrants.

LIQUIDITY AND CAPITAL RESOURCES

As discussed in our Form 10-K filed with the Securities and Exchange Commission for the year ended June 30, 2004, we have received a report from our independent registered public accounting firm regarding the consolidated financial statements for the fiscal year ended June 30, 2004 that includes an explanatory paragraph stating that the financial statements have been prepared assuming we will continue as a going concern. The explanatory paragraph states the following conditions which raise substantial doubt about our ability to continue as a going concern: (i) we have incurred recurring operating losses since inception, including a net loss of $6.5 million for the fiscal year ended June 30, 2004, and our accumulated deficit was $213.6 million at June 30, 2004 and (ii) we anticipate requiring additional financial resources to enable us to fund our operations at least through June 30, 2005. Management`s plans as to these matters are described below.

Except for the quarter ended September 30, 2003, in which we reported net income of approximately $3.4 million resulting principally from $6.5 million non-recurring license revenue recognized under a license and settlement agreement with ALZA Corporation, we have experienced net losses since our inception through December 31, 2004, and reported a net loss of $2.4 million for the quarter ended December 31, 2004. Our accumulated deficit was $219.1 million at December 31, 2004. We expect such losses to continue into the foreseeable future as we proceed with the research, development and commercialization of our technologies.

As of December 31, 2004, we had $14.0 million in cash, cash equivalents and investments compared to $20.5 million at June 30, 2004. The decrease of $6.5 million in cash, cash equivalents and investments balances primarily reflects the funding of ongoing operations. Our capital expenditures were zero and $5,000 for the six months ended December 31, 2004 and 2003, respectively. We expect our capital expenditures to remain at or near current spending levels.

Since our inception, we have financed our operations principally through public and private issuances of our common and preferred stock and funding from collaborative arrangements. We have used the net proceeds from the sale of the common and preferred stock for general corporate purposes, which may include funding research, development and product manufacturing, increasing our working capital, reducing indebtedness, acquisitions or investments in businesses, products or technologies that are complementary to our own, and capital expenditures. We expect that proceeds received from any future issuance of stock will be used for similar purposes.

In January 2004, we completed a private placement of 4,878,047 shares of common stock at $2.05 per share along with warrants, exercisable for a five-year period, to purchase 1,951,220 shares of common stock at $3.00 per share, resulting in net proceeds of approximately $9.4 million ("January 2004 Private Placement").

In June 2004, we completed a private placement, in which we issued and sold 2,234,779 shares of common stock and warrants, exercisable for a five-year period, to purchase 670,431 shares of common stock at $5.4075 per unit, resulting in net proceeds of approximately $11.2 million. ("June 2004 Private Placement").

We entered into registration rights agreements with the purchasers in the January 2004 Private Placement and the June 2004 Private Placement. Pursuant to the registration rights agreements, we filed with the Securities and Exchange Commission registration statements related to the shares issued to the purchasers and shares issuable upon the exercise of the warrants under the private placements. In the event we must suspend use of the registration statements for greater than 20 consecutive days or a total of 40 days in the aggregate during the time we are required to keep the registration statement effective under the registration rights agreements, then we must pay to each purchaser in cash 1.0% of the purchaser`s aggregate purchase price of the shares for the first month, as well as an additional 1.5% of the purchaser`s aggregate purchase price for each additional month thereafter, while the use of the registration statements has been suspended. We currently expect to be required to maintain availability of the registration statement for at least two years following the applicable closing.

Net cash used in operating activities in the six months ended December 31, 2004 was approximately $6.7 million, which consisted primarily of the net loss of $5.5 million, reduced by non-cash expenses of $486,000 related to the issuance of warrants to non-employees, a net increase of 70,000 in receivables and prepaid expenses and a decrease of accounts payable and other accrued liabilities totaling $1.6 million. Net cash provided by operating activities in the six months ended December 31, 2003 was approximately $1.9 million, which consisted primarily of the net income of $544,000, increased by non-cash depreciation expenses of $729,000, a net decrease of $89,000 in receivables and prepaid expenses, and a net increase of $508,000 in accounts payable and other accrued liabilities.

Net cash provided by investing activities in the six months ended December 31, 2004 was $1.6 million, which resulted primarily from maturities of available-for-sale investments. In the six months ended December 31, 2003, net cash provided by investing activities was approximately $3,000, which consisted primarily of proceeds from sale of equipment.

Net cash provided by financing activities in the six months ended December 31, 2004 was approximately $277,000, which was primarily attributable to proceeds received from the issuance of common stock upon exercise of warrants. In the six months ended December 31, 2003, net cash provided by financing activities was approximately $4.9 million, which resulted primarily from proceeds received from our January 2004 private placement.

We lease our facilities under operating leases. These leases expire between November 2006 and October 2007 with renewal options at the end of these lease terms.

Minimal annual rental commitments under the operating leases, excluding amounts to be received under subleases at December 31, 2004, are as follows (in thousands):


Year ending June 30, Operating Leases
2005 (Remaining term) $ 578
2006 1,177
2007 650
2008 65
$ 2,470






--------------------------------------------------------------------------------

We will be required to seek additional sources of funding to continue development and commercialization of our products. Based upon our current operating plan, we anticipate that our cash, cash equivalents and investments as of December 31, 2004 will enable us to maintain our current and planned operations at least through December 31, 2005, in the absence of additional financial resources. We may need to raise additional funds to continue our operations beyond December 31, 2005. In an effort to seek additional sources of financing, we may have to relinquish greater or all rights to products at an earlier stage of development or on less favorable terms than we would otherwise seek to obtain.

We are currently seeking additional collaborative agreements and licenses with corporate partners and may seek additional funding through public or private equity or debt financing or merger of our business. We may not be able to enter into any such agreements, however, or if entered into, any such agreements may not reduce or eliminate our need to seek additional funding. Additional financing to meet our funding requirements may not be available on acceptable terms or at all. If we raise additional funds by issuing equity securities, substantial dilution to existing stockholders may result.

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the accounts and classification of liabilities that may result from the matters discussed above.

RECENT ACCOUNTING PRONOUNCEMENTS

In December 2004, the FASB issued Statement No. 123 (revised 2004, or Statement 123R), "Share-Based Payment," effective beginning after June 15, 2005. FAS 123R supersedes APB Opinion No. 25, "Accounting for Stock Issued to Employees," and will require companies to recognize compensation expense, using a fair-value based method, for costs related to share-based payments including stock options and employee stock purchase plans. We will be required to implement FAS 123R no later than the fiscal year that begins July 1, 2005. The cumulative effect of adoption, if any, applied on a modified prospective basis, would be measured and recognized on July 1, 2005. We are currently evaluating option valuation methodologies and assumptions in light of FAS 123R, and therefore cannot estimate the impact of our adoption at this time. However, we expect that our adoption of FAS 123R will have a material adverse impact on our consolidated financial statements.

ADDITIONAL FACTORS THAT MAY AFFECT FUTURE RESULTS

The following risk factors outline certain risks and uncertainties concerning future results and should be read in conjunction with the information contained in this Quarterly Report on Form 10-Q. Any of these risk factors could materially and adversely affect our business, operating results and financial condition. Additional risks and uncertainties not presently known to us, or those we currently deem immaterial, may also materially harm our business, operating results and financial condition.

We have a history of losses and may never be profitable.

We have engaged in research and development activities since our inception. We incurred losses from operations of approximately $6.5 million, $15.7 million and $34.5 million, for our fiscal years ended June 30, 2004, 2003 and 2002, respectively. For the six months ended December 31, 2004, we incurred a net loss of $5.5 million. As of December 31, 2004, we had an accumulated deficit totaling approximately $219.1 million. The development and sale of our products will require completion of additional clinical trials and significant research and development activities. We expect to incur net losses for the foreseeable future as we continue with the research, development and commercialization of our products. Our ability to achieve profitability depends on the successful completion of our clinical trials, our additional research and development efforts, our ability to successfully commercially introduce our products, market acceptance of our products, the competitive position of our products and the other risk factors set forth in this report. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

Our ability to achieve profitability depends upon our research and development efforts and whether we can successfully develop and commercially introduce new products.

Our future success is dependent upon, among other factors, our ability to develop working products and our ability to successfully complete clinical trials. All of our potential products currently are in research, preclinical development or the early stages of clinical testing, and commercialization of those products will not occur for at least the next several years, if at all. The development of new drugs is a highly risky undertaking and there can be no assurance that our research and development efforts will be successful. Our VLTS 934 product and our cardiovascular therapies are new and may not lead to commercially viable pharmaceutical products. All of our products will require extensive additional research and development prior to any commercial introduction. There can be no assurance that any of our research and development and clinical trial efforts will result in viable new products. If our product and development efforts are unsuccessful, we will not achieve profitability and our business and results of operations would be adversely affected.

Our products are subject to extensive regulatory approval by the FDA and others, including with regard to completion of our clinical trials, which is expensive, time consuming and uncertain, and failure to obtain regulatory approval or successfully complete clinical trials may cause us to delay or withdraw the introduction of our products and could materially adversely affect our business and prospects.

We are subject to significant regulatory requirements, including the successful completion of clinical trials, prior to the commercialization of our products. Under the Federal Food, Drug and Cosmetic Act, the Public Health Services Act, and related regulations, the Food and Drug Administration, or FDA, regulates the development, clinical testing, manufacture, labeling, sale, distribution and promotion of drugs and biologics in the United States. Prior to market introduction in the United States, a potential drug or biological product must undergo rigorous clinical trials that meet the requirements of the FDA in order . . .



KURZFORM:


Valentis Announces Second Quarter Fiscal 2005 Financial Results
Monday February 14, 5:00 am ET


BURLINGAME, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Valentis, Inc. (Nasdaq: VLTS - News) today announced results for its second fiscal quarter ended December 31, 2004.
ADVERTISEMENT


Valentis reported a net loss for the three months ended December 31, 2004 of $2.4 million, or $0.19 per basic and diluted share on revenue of $124,000, compared to a net loss of $2.9 million, or $0.52 per basic and diluted share on revenue of $395,000 for the corresponding period of the prior year. The decrease in net loss primarily resulted from lower clinical trial expenditures partially offset by lower revenue. Net loss for the six months ended December 31, 2004 was $5.5 million, or $0.43 per basic and diluted share on revenue of $1.3 million, compared to a net income of $544,000, or $0.10 per basic and diluted share on revenue of $7.1 million for the corresponding period of the prior year. Net income of $544,000 for the six months ended December 31, 2003 was primarily attributable to a $6.5 million non-recurring revenue recognized under a license and settlement agreement.

On December 31, 2004, Valentis had approximately $14.0 million in cash, cash equivalents and short-term investments compared to approximately $20.5 million on June 30, 2004. The decrease of approximately $6.5 million primarily reflects the funding of ongoing operations.

Upcoming March Webcast at the Wells Fargo HealthCare Conference

Benjamin McGraw, Valentis` President and CEO, will present a company update at the Wells Fargo HealthCare conference in New York on Wednesday March 2, 2005 at 9:00am ET. Dr. McGraw`s presentation will be available via live webcast and may be accessed by visiting the "Investor Relations" section of the Valentis web site at http://www.valentis.com. The webcast will be archived on the same web site for approximately 30 days.

About Valentis

Valentis is creating innovative cardiovascular therapeutics. The company begins its product development at the stage of a validated target and applies its expertise in formulation, manufacturing, clinical development and regulatory affairs to create products that fill unmet medical needs. Valentis has a series of technologies that allow the company to generate novel therapeutics to treat a wide range of diseases. While Valentis is focusing its efforts on the development of novel cardiovascular therapeutics, its technologies are being applied by its collaborators for the development of therapeutics to treat a variety of indications including infectious diseases and cancer.

Additional information about Valentis can be found at http://www.valentis.com.

Statements in this press release that are not strictly historical are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. The words "believes," "expects," "intends," "anticipates," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Forward-looking statements include expectations about future levels of monthly cash expenditures, revenues and future operating results. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that could cause our actual results to differ materially from those projected in the forward-looking statement. Factors that could affect Valentis` actual results include uncertainties related to the timing and cost of additional clinical trials, uncertainties related to the results of clinical trials and the need for additional capital, the early stage of product development and ability to generate additional revenues from the licensing of Valentis` technologies. Further, there can be no assurance that necessary regulatory approvals will be obtained, that Valentis will be able to develop commercially viable therapeutics or that any of our programs will be partnered with pharmaceutical partners. Actual results may also differ from those projected in forward-looking statements due to risks and uncertainties that exist in Valentis` operations and business environments. These risks and uncertainties are described more fully in the Valentis Annual Report on Form 10-K, as amended, for the period ended June 30, 2004 and Quarterly Report on Form 10-Q for the period ended December 31, 2004, as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Valentis, Inc.

Selected Condensed Consolidated Financial Data

Statements of Operations
(in thousands, except per share amounts)

Three months ended Six months ended
December 31, December 31,
2004 2003 2004 2003
(unaudited) (unaudited)

License and other revenue $124 $395 $1,296 $7,104
Total revenue 124 395 1,296 7,104

Operating expenses:
Research and development 1,759 2,428 4,646 4,686
General and administrative 856 874 2,270 1,856
Total operating expenses 2,615 3,302 6,916 6,542
Income (loss) from operations (2,491) (2,907) (5,620) 562

Interest income 75 11 150 27
Other expenses -- -- (45) (45)
Net income (loss) $ (2,416) $ (2,896) $(5,515) $544

Income (loss) per share
Basic $(0.19) $(0.52) $(0.43) $0.10
Diluted $(0.19) $(0.52) $(0.43) $0.10

Weighted-average shares used
in computing income (loss)
per common share
Basic 12,986 5,622 12,942 5,588
Diluted 12,986 5,622 12,942 5,708

Balance Sheets
(in thousands)
December 31, 2004 June 30, 2004
Assets (unaudited) (*)
Cash , cash equivalents and
short-term investments $ 14,001 $ 20,450
Other current assets 927 856
Total current assets 14,928 21,306
Property and equipment, net 43 79
Goodwill and other assets, net 505 506
$ 15,476 $ 21,891

Liabilities and stockholders` equity
Accounts payable and accrued liabilities $ 2,388 $ 3,901
Deferred revenue -- 100
Stockholders` equity 13,088 17,890
$ 15,476 $ 21,891

* Derived from audited financial statements




--------------------------------------------------------------------------------
Source: Valentis, Inc.

[bioperformer]

Die gestern von VLTS abgelieferten Q2-Zahlen sind vom Markt mit zufriedener Stimmung beantwortet worden.
Einen beträchtlichen Anteil daran dürfte allein schon der Hinweis auf die aktuelle Finanzlage des Unternehmens bewirkt haben.
Die Aussage, man werde sicherlich ohne erforderliche Kapitalerhöhung bis mindestens Ende des Jahres auskommen, wurde von den Investoren überwiegend positiv bewertet.
Bleibt zu hoffen, daß wir auch von den forschenden Jungs und Mädels bald wieder Positives berichtet bekommen. Möglicherweise erfahren wir da ja schon bei deren nächstem "Info-Meeting" mehr...


Gruß, Bio

[bioperformer]

...ob es wohl heute noch für die "3" so ganz ohne News reicht ?

[bioperformer]

Valentis to Webcast Presentation at the Wells Fargo Health Care Conference
Tuesday February 22, 8:00 am ET


BURLINGAME, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Valentis Inc. (Nasdaq: VLTS - News) announced today that its presentation at the Wells Fargo Health Care conference will be webcast live and may be accessed by visiting the Investor Relations section of the Company`s website, www.valentis.com.
ADVERTISEMENT


Benjamin F. McGraw, III, Chairman, President and CEO of Valentis, will present a Company overview and an update of Valentis` product development programs. The presentation will be delivered at 9:00 am ET on Wednesday, March 2, 2005 from The St. Regis Hotel in New York. The presentation will be archived for 90 days.

About Valentis

Valentis is creating innovative cardiovascular therapeutics. The Company begins its product development at the stage of a validated target and applies its expertise in formulation, manufacturing, clinical development and regulatory affairs to create products that fill unmet medical needs. Valentis has a series of technologies that allow the Company to generate novel therapeutics to treat a wide range of diseases. Valentis is focusing its efforts on the development of novel cardiovascular therapeutics; its technologies are being applied by its collaborators for the development of therapeutics to treat a variety of indications including infectious diseases and cancer.

Additional information about Valentis can be found at www.valentis.com.




--------------------------------------------------------------------------------
Source: Valentis, Inc.

[bioperformer]

...heute fällt wohl diese wohl offensichlich eminent wichtige 3er-Marke.

Die Charttechniker im Bushland scheint das im Hinblick auf den nächsten, erst sehr weit entfernten Widerstand zu motivieren..

[bioperformer]

@all


Gestern der Aufschwung über die "magische Drei", und schon ist hier heute mal eine glatte Verdopplung bei der Menge der gehandelten Shares auszumachen.

Der Sammler der letzten Wochen wußte warum...

[bioperformer]

....sehen wir heute noch gar die 4 in USA?

Gibt es keine Kurse in Deutschland weil der Makler schon ins Wochenende gefahren ist, oder hat nur w:o diese nicht mehr aktualisiert?

[Kenny4Cash]

Der Kursanstieg in den USA ist ja nett nur kann ne 3,50 $ ohne jegliche News gehalten werden?
Im meine seit Dezember ist die um knapp 80% gestiegen und dass nur durch den Finazbericht.

Wie seht ihr die Lage?

MfG

Kenny4Cash

[bioperformer]

hallo kenny,

heute großes SL-Fishing bei den US-boys. War doch vor dem Anstieg der letzen Tage genau das Gleiche, gemäß dem Motto: schwach anfangen, stark nachlassen und zu guter letzt wieder auf das Anfangsniveau einpendeln...

Wer hier mit knapp bemessenen SL-Lines arbeitet hat da wenig Chancen seine Shares zu behalten. Um die Depots so richtig abzuräumen wird hier schon mit 15%-Schwankungen geackert.

Als Trostpflaster sei auf Mittwoch verwiesen, wenn da positive News anstehen werden die Shorties weinen, jedoch bestimmt keine Freudentränen...


Bis denne, Bio ( der seine Shares weiterpflegt)

[bioperformer]

@kenny4cash

was ich vorhin noch vergaß: Ich bin was die Käufe und den somit verbundenen Kursanstieg der letzten Tage anbelagt vollkommen anderer Ansicht im Hinblick auf das Kaufargument "gute Geschäftszahlen".

Unsere Käufer haben sicherlich nicht nur wegen der entspannten finanziellen Situation bei VLTS gekauft, da diese im Moment des Bekanntwerdens ja bereits Geschichte sind. Gehandelt wird immer der Ausblick, also das was vermutlich kommt.

Die Adressen, die seit September letzten Jahres ihre Shares nicht geschmissen haben wissen warum. Dort hat man eher noch zugekauft...

Wie gesagt, Mittwoch wissen wir mehr.....Die heutige Marktsituation ist durch die negativen Geschichten bei Biogen und Elan halt geradezu ein idealer Zeitpunkt zum Shorten..

[bioperformer]

@all


Presentation Wells Fargo Health Care Conference unter:


http://www.valentis.com/content/valentis_corp_presentation.p…

[bioperformer]

@all

SHORT INTEREST STAND 15.02.05


Feb. 15, 2005 390,185 99,835 3.91
Jan. 14, 2005 385,407 180,207 2.14
Dec. 15, 2004 376,584 178,593 2.11
Nov. 15, 2004 468,889 145,868 3.21
Oct. 15, 2004 776,142 784,154 1.00

[bioperformer]

Übertreibungphase nach unten genutzt, habe mir auf diesem Kurslevel mal wieder ein paar Stücke geleistet.

Sonst noch jemand mit von der Partie oder habt Ihr alle geschmissen?

[bioperformer]

....woher wollen die Shorties nur in nächster oder übernächster Zukunft all die lieben Shares herbekommen, die sie ja auch irgendwann mal covern müssen?

Was momentan grausam aussieht wird erst noch grausam werden...Fragt sich dann letztendlich nur für wen?

[Kenny4Cash]

Ich hab meine Posi bereits zu 3,28 geschmissen und hab bei 2,00 - 2,20 vor wieder einzusteigen.
Jedoch denk ich mal, das erstmal die treibende Kraft raus is, was man schön an den Umsätzen sieht.
Vielleicht kommt das selbe Spiel wieder, einer kauft groß ein und hält den Kurs um die 2,20 und dann gehts wieder Richtung norden, mal sehn und abwarten.

Kenny4Cash

[bioperformer]

Hallo Kenny,

ich glaube daß der(die)Käufer, der den letzten Anstieg hochgekauft hat, weit mehr Shares aufsammelte als da jetzt im im Zuge des Kurseinbruches versilbert wurden.

Bei den Kursen im Bereich über 3,40 US$ wurden so richtige kleine "Volumenrekorde" aufgestellt, bei der anschließenden Talfahrt sind dann kaum noch große Mengen gehandelt worden.

Genauso deftig wie der vermutlich gebastelte Einbruch auch war, eine Erholung könnte jedoch ebenfalls heftig ausfallen (Marktenge). Vorgestern habe ich mal bei VLTS nachgefragt wie deren Interpretation des Kursrutsches so aussieht, habe jedoch noch kein Feedback bekommen.

Mit der kürzlich getätigten Wells Fargo Health Care Konferenz denke ich hat man fachlich nicht den Anstoß zum kleinen Ausverkauf gegeben, denn da wären wohl wesentlich mehr Shares über den Tresen gegangen.

Wie auch immer, es werden auch wieder grüne Zeiten kommen...

Bis denne, Bio

[bioperformer]

netter Wochenausklang....

[bioperformer]

Sieht so aus als wenn das Terrain um die 3$-Marke bald wieder fest im Griff ist.

Hat heute immerhin schlappe 1 1/2 Stunden gedauert, bis die ersten Shares über den Tresen gingen. Viele Stücke werden da auf diesem Kursniveau nicht mehr zu holen sein, wenn nichts unerwartetes passiert.

Nicht vergessen auch mal ein Auge auf den Langfristchart werfen, VLTS hatte immer wieder teils schon deftige Kursanstiege zu verzeichnen.
Der Albtraum für die Shorties die ja zuletzt auch ganz gut verdient hatten....

[bioperformer]

SHORT INTEREST - Stand 15.03.05


Mar. 15, 2005 437,529 127,807 3.42
Feb. 15, 2005 390,185 99,835 3.91
Jan. 14, 2005 385,407 180,207 2.14
Dec. 15, 2004 376,584 178,593 2.11
Nov. 15, 2004 468,889 145,868 3.21
Oct. 15, 2004 776,142 784,154 1.00

[bioperformer]

Press Release Source: Valentis, Inc.


Valentis Announces Initiation of Phase IIb Clinical Trial of VLTS-934 for the Treatment of Peripheral Arterial Disease
Thursday March 31, 7:30 am ET


BURLINGAME, Calif., March 31 /PRNewswire-FirstCall/ -- Valentis, Inc. (Nasdaq: VLTS - News) announced today it initiated patient dosing on schedule in a Phase IIb clinical trial to evaluate the safety and efficacy of VLTS-934. VLTS-934 is a non-ionic, block copolymer known as a poloxamer, which appears to produce a therapeutic benefit in ischemic tissue.
In this randomized, double-blinded and placebo-controlled trial, approximately 148 patients with peripheral arterial disease, specifically intermittent claudication, will receive either VLTS-934 or a saline placebo. The primary endpoint of the trial is improvement in exercise tolerance. Valentis plans to complete enrollment in the first quarter of 2006 and data are expected mid-2006.

This VLTS-934 Phase IIb trial follows a previously completed 105 patient Phase IIa clinical trial that compared VLTS-934 to an investigational angiogenic agent. In that trial, VLTS-934 demonstrated a statistically significant improvement in exercise tolerance and ankle-brachial index compared to baseline. The Phase IIb trial has a virtually identical design to the Phase IIa trial but includes a comparison to patients treated with a saline placebo.

The estimated market for a safe and efficacious product to treat intermittent claudication is in excess of $1 billion. Approximately five percent of adults in the United States over the age of 55 suffer from the intermittent claudication, a form of peripheral arterial disease. Symptoms of intermittent claudication include leg pain during exercise due to a lack of adequate blood flow.

Patients interested in participating in this trial may contact Linda Sobolak at 650-697-1900 ext.263, email: [e-mail].

About Valentis

Valentis is focused on the creation of innovative cardiovascular therapeutics. The Company begins its product development at the stage of a known molecule or protein and applies its expertise in formulation, manufacturing, clinical development and regulatory affairs to create products that fill unmet medical needs. Valentis has a series of technologies that allow the company to generate novel therapeutics to treat a wide range of diseases. While Valentis is focusing its efforts on the development of novel cardiovascular therapeutics, its technologies are being applied by its collaborators for the development of therapeutics to treat a variety of indications including infectious diseases and cancer.


Additional information about Valentis can be found at www.valentis.com.
This press release contains forward-looking statements regarding plans for completing patient enrollment in the first quarter of 2006, the expectation of clinical trial data in the third quarter of 2006, statements regarding the potential therapeutic benefit and efficacy of VLTS 934 and Valentis ability to develop potential products based on VLTS 934 for treatment of peripheral arterial disease. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict. In particular, results obtained regarding VLTS 934 as a result of the Phase IIa clinical trial of Valentis` Deltavasc(TM) product may not be predictive of results that may be obtained in a Phase IIb trial of VLTS 934 in peripheral arterial disease. Additional factors that could cause actual results to differ include risks related to the conduct of a Phase IIb clinical trial of VLTS 934, potential changes in study protocols, ability to enroll additional patients, ability to protect the intellectual property related to development of VLTS 934, the need for additional capital, uncertainties related to the timing of completing clinical trials, uncertainties related to the costs of completing clinical trials and whether the Phase IIb clinical trial results will validate and support the safety and efficacy of a VLTS 934 based product. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Valentis will be able to commercially develop such product. Actual results may also differ from those projected in forward- looking statements due to risks and uncertainties that exist in the Company`s operations and business environments. These risks and uncertainties are described more fully in the Valentis Annual Report on Form 10-K for the period ended June 30, 2004 and quarterly report of Form 10-Q for the period ended December 31, 2004, as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.




--------------------------------------------------------------------------------
Source: Valentis, Inc.